Phase I Trial of Silymarin for Chronic Liver Diseases (SyNCH)

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study is to determine the safety and tolerability of different dosages of silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.

Condition or disease	Intervention/treatment	Phase
Hepatitis C; Non-Alcoholic Fatty Liver Disease	Drug: Placebo; Drug: Silymarin	Phase 1

National Center for Complementary and Integrative Health (NCCIH) has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	56 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:	Basic Science
Official Title:	Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered Silymarin (Legalon) in Non-Cirrhotic Subjects With Chronic Hepatitis C or Non-Alcoholic Fatty Liver Disease
Study Start Date :	November 2006
Actual Primary Completion Date :	January 2008
Actual Study Completion Date :	February 2008

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Group 1; Placebo and 140 mg single dose + every 8 hours	Drug: Placebo; Placebo Drug: Silymarin; 140 mg every 8 hours; Other Name: Legalon
Group 2; Placebo and 280 mg single dose	Drug: Placebo; Placebo Drug: Silymarin; 280 mg single dose; Other Name: Legalon
Group 3; Placebo and 280mg every 8 hours	Drug: Placebo; Placebo Drug: Silymarin; 280 mg every 8 hours; Other Name: Legalon
Group 4; Placebo and 280 single dose + every 8 hours	Drug: Placebo; Placebo Drug: Silymarin; 280 mg single dose + every 8 hours; Other Name: Legalon
Group 5; Placebo and 560 mg single dose + every 8 hours	Drug: Placebo; Placebo Drug: Silymarin; 560 mg single dose + every 8 hours; Other Name: Legalon
Group 6; Placebo and 560 mg single dose + every 8 hours	Drug: Placebo; Placebo Drug: Silymarin; 560 mg single dose + every 8 hours; Other Name: Legalon
Group 7; Placebo and 700 mg single dose + every 8 hours	Drug: Placebo; Placebo Drug: Silymarin; 700 mg single dose + every 8 hours; Other Name: Legalon

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Adverse events [ Time Frame: 10 days ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria

Subjects will be eligible for enrollment in this study if they meet the following criteria:

• Males or females; age at least 18 years at screening
• Abnormal ALT > 65 IU/L (ie, approximately 1.5 x upper limit of normal)
• Negative urine pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of silymarin. Females of childbearing potential must be using two reliable forms of effective contraception during the study (while on drug and during follow-up)
• Hepatitis C virus (HCV) patients
• Previous treatment with any interferon-based therapy without sustained virological response.
• Serum HCV RNA above quantifiable level of detection by the assay, within 1 year of screening and after the end of therapy
• No antiviral therapy for at least 6 months prior to screening visit
• Nonalcoholic fatty liver disease (NAFLD) patients:
• Liver biopsy compatible with NAFLD within 3 years of screening
• Absence of other liver diseases by serological screening (anti-HCV, HBsAg), historical serological data from within 3 years of screening is acceptable.
• Before entering the study, subjects must agree not to consume alcohol for 48 hours prior to PK sampling days or while on study.

Exclusion criteria

Subjects with any of the following will not be eligible for participation:

• Use of silymarin or other milk thistle preparations within 30 days of screening
• Use of other antioxidants such as vitamin E, vitamin C, glutathione, alpha-tocopherol, within 30 days of screening. A multivitamin at standard doses will be allowed.
• Allergy/sensitivity to milk thistle or its preparations
• Use of silymarin or other antioxidants (as above) during the screening period.
• Use of warfarin, metronidazole or chronic use of acetaminophen greater than two gram per day
• Previous liver biopsy that demonstrated presence of cirrhosis
• Previous liver biopsy that demonstrated greater than or equal to 15% steatosis or evidence of steatohepatitis for HCV cohort
• Positive test for anti-HIV or HBsAg within 3 years of screening
• Positive urine drug screen for drugs of abuse at screening
• Alcohol consumption of more than one drink or equivalent (>12 grams) per day. Patients who consumed more than this in the past must have maintained a level 12 grams or less per day of alcohol consumption for at least six months prior to screening.
• History of other chronic liver disease, including metabolic diseases, documented by appropriate test(s)
• Women with ongoing pregnancy or breast-feeding, or contemplating pregnancy
• Platelet count <130,000 cells/mm3.
• Serum creatinine level >1.5 times the upper limit of normal at screening, or CrCl 60 cc/min, or currently on dialysis. The creatinine clearance (CrCl) will be calculated according to Cockcroft-Gault.
• Evidence of alcohol or drug abuse within 6 months prior to screening
• Evidence of decompensated liver disease defined as any of the following: serum albumin <3.2 g/dl, total bilirubin > 1.5 mg/dl, or PT/INR > 1.3 times normal at screening, or history or presence of ascites or encephalopathy, or bleeding from esophageal varices
• History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, coronary artery disease, or active gastrointestinal conditions that might interfere with drug absorption)
• History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hepatitis, autoimmune hemolytic anemia, severe psoriasis, rheumatoid arthritis) that could affect inflammatory biomarkers
• History of solid organ or bone marrow transplantation
• History of thyroid disease poorly controlled on prescribed medications
• Use of oral steroids within 30 days prior to screening
• Concurrent medications that are CYP3A4 inducers
• Inability or unwillingness to provide informed consent or abide by the study protocol

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, North Carolina
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
University of Pittsburgh, Graduate School of Public Health
Pittsburgh, Pennsylvania, United States, 15261

Sponsors and Collaborators

National Center for Complementary and Integrative Health (NCCIH)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

Principal Investigator:	K. Rajender Reddy, MD	University of Pennsylvania
Principal Investigator:	Victor Navarro, MD	Thomas Jefferson University
Principal Investigator:	Nezam Afdhal, MD	Beth Israel Deaconess Medical Center
Principal Investigator:	Michael Fried, MD	University of North Carolina

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Meyers CM, Doo E, Fried MW. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos. 2011 Dec;39(12):2182-90. doi: 10.1124/dmd.111.040212. Epub 2011 Aug 24.

Responsible Party:	SyNCH Steering Committee, NCCAM/NIDDK/UNC/UPenn/TJU/BIDMC/UPitt
ClinicalTrials.gov Identifier:	NCT00389376 History of Changes
Other Study ID Numbers:	U01AT003566-01 ( U.S. NIH Grant/Contract ); NIH grant # U01-AT0035661
First Posted:	October 18, 2006
Last Update Posted:	February 20, 2008
Last Verified:	February 2008

Additional relevant MeSH terms:

Hepatitis; Hepatitis C; Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease; Digestive System Diseases; Hepatitis, Viral, Human; Virus Diseases	Flaviviridae Infections; RNA Virus Infections; Silymarin; Antioxidants; Molecular Mechanisms of Pharmacological Action; Protective Agents; Physiological Effects of Drugs